1) Strategy & Leadership
- Insulet Corporation reported a strong start to 2026, emphasizing growth momentum and margin expansion.
- The company is focused on strategic priorities: accelerating innovation, developing core markets, strengthening commercial capabilities, and leveraging financial strength for profitable growth.
- CEO Ashley McEvoy expressed confidence in the company's potential, highlighting a culture of patient focus and an entrepreneurial spirit.
- The company is investing in its sales force and enhancing its commercial engine to drive market expansion.

2) Financial & Segment Results
- Q1 2026 total revenues reached $762 million, a 34% increase YoY, with 30% growth on a constant currency basis.
- Omnipod revenue grew 33% on a constant currency basis, with U.S. revenue up 28% and international revenue up 45%.
- Adjusted EPS increased by 40% to $1.42, driven by top-line growth and margin expansion.
- The company raised its full-year revenue growth guidance from 20%-22% to 21%-23%.

3) Problems / Headwinds
- Insulet experienced greater than normal seasonality in Q1, attributed to the annual reset of deductibles affecting patient co-pays.
- There was a noted sequential decline in new customer starts in the U.S., although month-on-month trends improved towards the end of the quarter.
- The company faced challenges related to a voluntary medical device correction, but it does not believe this impacted new customer starts significantly.

4) Operational or Product Plans
- Insulet is set to launch the Omnipod 5 integration with the Libre 3 Plus sensor, targeting an additional 450,000 potential users.
- The company is advancing its innovation pipeline, including the upcoming Omnipod 6 and a fully closed-loop system for type 2 diabetes expected in 2028.
- Investments in R&D and commercial capabilities are ramping up to support future growth and market penetration, particularly in type 2 diabetes.

5) Guidance & Outlook / Investor Angle
- For Q2 2026, Insulet expects Omnipod revenue growth of 21%-23% and total company revenue growth of 20%-22%.
- The full-year guidance for total Omnipod revenue growth is now 22%-24%, with international growth expected at 26%-28%.
- The company anticipates continued positive pricing trends and is focused on expanding access and improving retention rates, particularly in the type 2 segment.

Bottom line: Insulet's robust Q1 performance and strategic initiatives position it well for sustained growth, despite short-term headwinds. The company's focus on innovation and market expansion, particularly in the underpenetrated type 2 diabetes segment, supports a positive outlook for shareholders.